New European medical device regulation: How the French ecosystem should seize the opportunity of the EUDAMED and the UDI system, while overcoming the constraints thereof.


Journal

Therapie
ISSN: 0040-5957
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 25 10 2018
accepted: 05 11 2018
pubmed: 2 1 2019
medline: 18 12 2019
entrez: 2 1 2019
Statut: ppublish

Résumé

The European regulation governing the placing on the market of medical devices (MD) provides for the gradual and mandatory phasing-in, within the European Union, of a unique device identification (UDI) system and a European database (EUDAMED) aimed at improving traceability and transparency of the market. The deployment of these tools will have a significant impact on the stakeholders of the medical device world (companies, health institutions, healthcare professionals, competent authorities, etc.). A strengths/weaknesses/opportunities/threats (SWOT) analysis conducted among the think tank participants shows real support for the objectives but also distinguishes a great deal of issues relating to the implementation of these tools. An inventory of the current traceability tools and databases used in France was then carried out to measure the gaps between the requirements of the European regulation and the current situation revealing that EUDAMED and the UDI system will ultimately have to slot into a complex and poorly interoperable ecosystem. An essential first step to facilitate this integration will be to increase the number of educational, awareness-raising and information initiatives for the stakeholders concerned. Several other recommendations were put forward to support the implementation of EUDAMED and the UDI system in France and thus enable their promises to crystallise in the future.

Identifiants

pubmed: 30598315
pii: S0040-5957(18)30255-5
doi: 10.1016/j.therap.2018.12.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-85

Investigateurs

Charles-Emmanuel Barthélémy (CE)
Pierre-Yves Chambrin (PY)
Gilles Hebbrecht (G)
Jeanine Lafont (J)
Patrick Mazaud (P)
Lionel Pazart (L)
Philippe Soly (P)
Cécile Vaugelade (C)
Fanny Wilquin-Bequet (F)

Informations de copyright

Copyright © 2018 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Dorothée Camus (D)

SNITEM, 39, rue Louis-Blanc, 92400 Courbevoie, France. Electronic address: dorothee.camus@snitem.fr.

Dominique Thiveaud (D)

Euro-Pharmat, 31300 Toulouse, France.

Anne Josseran (A)

Sanofi-Aventis, 94250 Gentilly, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH